secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001437749-24-017040
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax Q1 net loss widens to $5.6M; cash drops to $0.8M, raising going-concern risk
--------------------------------------------------------------------------------

- Net loss of $5.6M ($2.47 per share) vs $4.0M ($2.30 per share) in Q1 2023.
- Cash balance fell to $768,859 from $6.45M at Dec 31, 2023, a decline of ~$5.7M.
- R&D expenses rose to $4.43M from $2.82M, driven by manufacturing costs for clinical trials.
- Phase 2 GEO-CM04S1 COVID vaccine booster trial showed statistically significant neutralizing antibody increases against multiple variants.
- Gedeptin Phase 1/2 for head and neck cancer completed enrollment; expected to complete Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774924017040/0001437749-24-017040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774924017040/govx20240514_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-017040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer